Header Logo

Connection

JAMES C YAO to Middle Aged

Back to Details
This is a "connection" page, showing publications JAMES C YAO has written about Middle Aged.
JAMES C YAO
Connection Strength
0.868
Middle Aged
  1. Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market. JNCI Cancer Spectr. 2021 08; 5(4).
    View in: PubMed
    Score: 0.028
  2. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas. 2019 03; 48(3):381-386.
    View in: PubMed
    Score: 0.024
  3. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents. Abdom Radiol (NY). 2018 07; 43(7):1661-1669.
    View in: PubMed
    Score: 0.023
  4. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 2018 02 15; 124(4):807-815.
    View in: PubMed
    Score: 0.022
  5. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 01; 3(10):1335-1342.
    View in: PubMed
    Score: 0.022
  6. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol. 2017 May 20; 35(15):1695-1703.
    View in: PubMed
    Score: 0.021
  7. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol. 2016 11 10; 34(32):3906-3913.
    View in: PubMed
    Score: 0.021
  8. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016 09; 24(9):3695-703.
    View in: PubMed
    Score: 0.020
  9. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 05; 387(10022):968-977.
    View in: PubMed
    Score: 0.019
  10. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015 Jun; 22(3):431-41.
    View in: PubMed
    Score: 0.019
  11. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015 Mar; 44(2):190-7.
    View in: PubMed
    Score: 0.018
  12. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015 Mar; 44(2):181-9.
    View in: PubMed
    Score: 0.018
  13. Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values. Radiology. 2013 Dec; 269(3):758-67.
    View in: PubMed
    Score: 0.017
  14. Improving the success rate of gluteal intramuscular injections. Pancreas. 2013 Jul; 42(5):878-82.
    View in: PubMed
    Score: 0.016
  15. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012 Apr; 41(3):461-6.
    View in: PubMed
    Score: 0.015
  16. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011 Dec; 96(12):3741-9.
    View in: PubMed
    Score: 0.015
  17. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol. 2011 Mar; 196(3):569-76.
    View in: PubMed
    Score: 0.014
  18. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6):514-23.
    View in: PubMed
    Score: 0.014
  19. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg. 2010 Jun; 251(6):1117-21.
    View in: PubMed
    Score: 0.013
  20. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010 Jan 01; 28(1):69-76.
    View in: PubMed
    Score: 0.013
  21. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 08; 360(2):195-7.
    View in: PubMed
    Score: 0.012
  22. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008 Sep 10; 26(26):4311-8.
    View in: PubMed
    Score: 0.012
  23. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008 Aug 15; 123(4):867-73.
    View in: PubMed
    Score: 0.012
  24. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18):3063-72.
    View in: PubMed
    Score: 0.012
  25. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008 Apr; 17(4):959-65.
    View in: PubMed
    Score: 0.011
  26. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23.
    View in: PubMed
    Score: 0.011
  27. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008 Jan; 19(1):145-51.
    View in: PubMed
    Score: 0.011
  28. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007 Dec; 14(12):3492-500.
    View in: PubMed
    Score: 0.011
  29. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40.
    View in: PubMed
    Score: 0.010
  30. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15; 104(8):1590-602.
    View in: PubMed
    Score: 0.010
  31. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103.
    View in: PubMed
    Score: 0.009
  32. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71.
    View in: PubMed
    Score: 0.009
  33. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17.
    View in: PubMed
    Score: 0.009
  34. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. 2024 Jun 03; 29(6):e803-e810.
    View in: PubMed
    Score: 0.009
  35. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark. 2024; 41(1):83-91.
    View in: PubMed
    Score: 0.008
  36. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321.
    View in: PubMed
    Score: 0.008
  37. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
    View in: PubMed
    Score: 0.007
  38. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12.
    View in: PubMed
    Score: 0.007
  39. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas. 2021 04 01; 50(4):506-512.
    View in: PubMed
    Score: 0.007
  40. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2022; 112(1):34-42.
    View in: PubMed
    Score: 0.007
  41. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846.
    View in: PubMed
    Score: 0.007
  42. Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology. 2021; 111(9):850-862.
    View in: PubMed
    Score: 0.007
  43. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
    View in: PubMed
    Score: 0.006
  44. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas. 2019 Nov/Dec; 48(10):1373-1379.
    View in: PubMed
    Score: 0.006
  45. Tamoxifen-induced thrombocytopenia. Am J Clin Oncol. 1999 Oct; 22(5):529-32.
    View in: PubMed
    Score: 0.006
  46. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118.
    View in: PubMed
    Score: 0.006
  47. Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas. 2019 04; 48(4):510-513.
    View in: PubMed
    Score: 0.006
  48. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol. 2018 Jun; 25(6):1709-1715.
    View in: PubMed
    Score: 0.006
  49. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Na?ve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2018 07; 23(7):766-e90.
    View in: PubMed
    Score: 0.006
  50. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol. 2017 Dec; 40(6):555-560.
    View in: PubMed
    Score: 0.006
  51. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan; 109(1):174-181.
    View in: PubMed
    Score: 0.006
  52. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 10; 18(10):1411-1422.
    View in: PubMed
    Score: 0.005
  53. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
    View in: PubMed
    Score: 0.005
  54. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. Pancreas. 2017 07; 46(6):751-757.
    View in: PubMed
    Score: 0.005
  55. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 2018; 106(3):211-220.
    View in: PubMed
    Score: 0.005
  56. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
    View in: PubMed
    Score: 0.005
  57. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1? Clin Endocrinol (Oxf). 2017 Jun; 86(6):791-797.
    View in: PubMed
    Score: 0.005
  58. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135.
    View in: PubMed
    Score: 0.005
  59. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery. 2017 03; 161(3):753-759.
    View in: PubMed
    Score: 0.005
  60. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct 25; 7(43):69916-69926.
    View in: PubMed
    Score: 0.005
  61. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2017 01; 21(1):155-163.
    View in: PubMed
    Score: 0.005
  62. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf). 2016 09; 85(3):400-7.
    View in: PubMed
    Score: 0.005
  63. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016 Jun; 15(2):e1-7.
    View in: PubMed
    Score: 0.005
  64. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer. 2015 Dec; 22(6):933-40.
    View in: PubMed
    Score: 0.005
  65. Role and Operative Technique of Portal Venous Tumor Thrombectomy in Patients with Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2015 Nov; 19(11):2011-8.
    View in: PubMed
    Score: 0.005
  66. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
    View in: PubMed
    Score: 0.005
  67. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Neuroendocrinology. 2015; 102(1-2):18-25.
    View in: PubMed
    Score: 0.005
  68. Expression of estrogen-induced genes and estrogen receptor ? in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas. 2014 Oct; 43(7):996-1002.
    View in: PubMed
    Score: 0.004
  69. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014 Aug 02; 14:561.
    View in: PubMed
    Score: 0.004
  70. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014 Aug; 138(8):1027-36.
    View in: PubMed
    Score: 0.004
  71. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14.
    View in: PubMed
    Score: 0.004
  72. Effect of pre-enhancement set point on computed tomographic perfusion values in normal liver and metastases to the liver from neuroendocrine tumors. J Comput Assist Tomogr. 2014 Jul-Aug; 38(4):526-34.
    View in: PubMed
    Score: 0.004
  73. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9.
    View in: PubMed
    Score: 0.004
  74. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013 Jul; 37(7):1695-700.
    View in: PubMed
    Score: 0.004
  75. Clinical burden of illness in patients with neuroendocrine tumors. Pancreas. 2012 Oct; 41(7):1058-62.
    View in: PubMed
    Score: 0.004
  76. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res. 2012 Nov 15; 72(22):5683-91.
    View in: PubMed
    Score: 0.004
  77. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2012 Sep; 199(3):602-8.
    View in: PubMed
    Score: 0.004
  78. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10; 378(9808):2005-2012.
    View in: PubMed
    Score: 0.004
  79. EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci. 2012 Mar; 57(3):791-800.
    View in: PubMed
    Score: 0.004
  80. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
    View in: PubMed
    Score: 0.003
  81. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15; 116(6):1446-53.
    View in: PubMed
    Score: 0.003
  82. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009 Mar 01; 15(5):1821-9.
    View in: PubMed
    Score: 0.003
  83. Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res. 2009 Feb 03; 28:14.
    View in: PubMed
    Score: 0.003
  84. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol. 2009 Jan; 16(1):42-50.
    View in: PubMed
    Score: 0.003
  85. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer. 2008 Aug 01; 113(3):461-9.
    View in: PubMed
    Score: 0.003
  86. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol. 2008 Oct; 15(10):2684-91.
    View in: PubMed
    Score: 0.003
  87. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70.
    View in: PubMed
    Score: 0.003
  88. Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer. 2008 Jan; 47(1):84-92.
    View in: PubMed
    Score: 0.003
  89. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci. 2008; 38(3):195-209.
    View in: PubMed
    Score: 0.003
  90. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90.
    View in: PubMed
    Score: 0.003
  91. The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res. 2007 Aug 15; 13(16):4704-12.
    View in: PubMed
    Score: 0.003
  92. Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. Endocr Relat Cancer. 2007 Jun; 14(2):483-92.
    View in: PubMed
    Score: 0.003
  93. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol. 2007 Jul; 20(7):802-10.
    View in: PubMed
    Score: 0.003
  94. [Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11.
    View in: PubMed
    Score: 0.003
  95. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 01; 109(1):33-40.
    View in: PubMed
    Score: 0.003
  96. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis. 2006; 23(7-8):401-10.
    View in: PubMed
    Score: 0.003
  97. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80.
    View in: PubMed
    Score: 0.003
  98. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul; 24(4):353-7.
    View in: PubMed
    Score: 0.003
  99. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006 May; 30(5):643-53.
    View in: PubMed
    Score: 0.002
  100. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Feb 01; 24(4):663-7.
    View in: PubMed
    Score: 0.002
  101. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol. 2005 Dec; 18(12):1632-40.
    View in: PubMed
    Score: 0.002
  102. Carcinoid tumors of the duodenum. Surgery. 2005 Dec; 138(6):971-7; discussion 977-8.
    View in: PubMed
    Score: 0.002
  103. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 01; 23(28):6957-65.
    View in: PubMed
    Score: 0.002
  104. Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5778-83.
    View in: PubMed
    Score: 0.002
  105. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod Pathol. 2005 Aug; 18(8):1079-87.
    View in: PubMed
    Score: 0.002
  106. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res. 2005 Jun 01; 65(11):4809-16.
    View in: PubMed
    Score: 0.002
  107. Drastic down-regulation of Kr?ppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 2005 Apr 01; 65(7):2746-54.
    View in: PubMed
    Score: 0.002
  108. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64.
    View in: PubMed
    Score: 0.002
  109. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1386-93.
    View in: PubMed
    Score: 0.002
  110. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer. 2005; 8(1):18-28.
    View in: PubMed
    Score: 0.002
  111. Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis. 2005; 22(3):205-13.
    View in: PubMed
    Score: 0.002
  112. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93.
    View in: PubMed
    Score: 0.002
  113. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36.
    View in: PubMed
    Score: 0.002
  114. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
    View in: PubMed
    Score: 0.002
  115. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004; 21(8):755-64.
    View in: PubMed
    Score: 0.002
  116. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003 Dec 15; 9(17):6371-80.
    View in: PubMed
    Score: 0.002
  117. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2.
    View in: PubMed
    Score: 0.002
  118. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003 Jul-Aug; 9(4):261-7.
    View in: PubMed
    Score: 0.002
  119. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol. 2003 Apr; 26(2):165-70.
    View in: PubMed
    Score: 0.002
  120. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001 Feb; 24(1):91-5.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.